Mutation analysis of 24 known cancer genes in the NCI-60 cell line set

Mol Cancer Ther. 2006 Nov;5(11):2606-12. doi: 10.1158/1535-7163.MCT-06-0433. Epub 2006 Nov 6.


The panel of 60 human cancer cell lines (the NCI-60) assembled by the National Cancer Institute for anticancer drug discovery is a widely used resource. The NCI-60 has been characterized pharmacologically and at the molecular level more extensively than any other set of cell lines. However, no systematic mutation analysis of genes causally implicated in oncogenesis has been reported. This study reports the sequence analysis of 24 known cancer genes in the NCI-60 and an assessment of 4 of the 24 genes for homozygous deletions. One hundred thirty-seven oncogenic mutations were identified in 14 (APC, BRAF, CDKN2, CTNNB1, HRAS, KRAS, NRAS, SMAD4, PIK3CA, PTEN, RB1, STK11, TP53, and VHL) of the 24 genes. All lines have at least one mutation among the cancer genes examined, with most lines (73%) having more than one. Identification of those cancer genes mutated in the NCI-60, in combination with pharmacologic and molecular profiles of the cells, will allow for more informed interpretation of anticancer agent screening and will enhance the use of the NCI-60 cell lines for molecularly targeted screens.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Cell Line, Tumor*
  • DNA Mutational Analysis
  • Exons
  • Gene Deletion
  • Gene Expression Profiling
  • Genes, Neoplasm*
  • Homozygote
  • Humans
  • Mutation*
  • RNA Splice Sites


  • RNA Splice Sites